SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for the crypto community as investors debate its long-term viability against competing meme coins, with ongoing discussions centered on token burn mechanisms and the potential for a market rotation. While some remain bullish, citing long-term utility and historical trends, others are vocalizing concerns about its current performance and the emergence of newer blockchain-based alternatives.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme downward pressure, with the community actively debating whether the current price action represents a historic capitulation or a terminal collapse of the project. Investors are expressing deep frustration over persistent sell-offs, with many highlighting the lack of a meaningful bounce compared to other assets and growing uncertainty regarding future utility and institutional support.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community remains deeply divided between long-term investors adding to their positions during market-wide dips and skeptics who frequently label the project a scam due to its stagnant performance and perceived lack of utility. Traders are currently focused on technical resistance levels and debating whether the recent launch of related ecosystem projects indicates abandonment of the main token or a broader strategic expansion.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as it faces a high-stakes legal challenge from 12 state attorneys general attempting to block its $110 billion merger with Warner Bros. Discovery despite prior federal approval. Community discussion is polarized, with many investors viewing the lawsuit as politically motivated theater while others express significant concern over the potential for costly ticking fees and further financial strain on the company.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community debates its shift to a paid subscription model for API access, which many view as a pivotal move toward long-term profitability. Investors are heavily focused on the protocol's role in the oracle and real-world asset (RWA) sectors, often comparing its growth potential and data infrastructure to industry peers.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Community members are actively debating the long-term utility of this Bitcoin-native asset, with supporters touting its decentralized structure while skeptics caution against its volatile price action and distribution. The conversation remains heavily focused on its role as a potential store of value within the Bitcoin ecosystem and the strength of its dedicated following.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

Technology sector funds like XLK are facing heightened volatility as investors pivot from broad AI spending excitement to demanding concrete evidence of revenue and margin growth. The market is currently grappling with a rotation toward defensive sectors and financials, leaving tech at a pivotal technical test as traders weigh AI-driven cloud demand against concerns over elevated valuations and the impact of evolving U.S. trade policy.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending as traders debate its potential for a major price breakout, with community sentiment divided between bullish expectations of a short-squeeze toward new highs and bearish concerns regarding token inflation and competition. Discussions are heavily focused on Solana's role in institutional AI infrastructure, its resilience against market volatility, and the impact of upcoming legislative updates.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently trending as investors focus on recent in-licensing of VEPPANU, the first FDA-approved PROTAC therapy, which the community views as a potential blockbuster growth driver for the oncology franchise. While the stock has faced downward pressure, long-term investors are highlighting its status as a profitable commercial biotech with a low valuation, eagerly awaiting further pipeline data and the potential for a positive valuation shift.

Anthropic

Anthropic is trending as it rapidly expands its computing infrastructure through major deals with SpaceX and AMD, while aggressively competing in the enterprise AI space with its latest Claude models. The community remains focused on the company's valuation trajectory, high infrastructure spending, and the intense race to maintain a competitive advantage against other frontier AI labs ahead of a potential IPO.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, July 24, 2026 SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis

Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in...

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Equity

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.


Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 26, 2026 SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 3, 2026 SAN FRANCISCO, June 3, 2026 /PRNewswire/ --Nektar Therapeutics (NASDAQ: NKTR) today announced...

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PR Newswire SAN FRANCISCO, May 27, 2026 SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar...

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

Key PointsProsight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter...

Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.97	--	--	N/A
Q1 '26	-$1.58	-$1.82	-15.02%	MISSED
Q4 '25	-$2.47	-$1.78	28.06%	BEAT
Q3 '25	-$2.68	-$1.87	30.35%	BEAT
Q2 '25	-$3.03	-$2.95	2.56%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

NKTRNektar Therapeutics

Upcoming Earnings: Q2 '26

Historical Earnings

Latest NKTR News